Insights & news

Comparison of Regulatory Outcome of EMA and FDA New Medicine Marketing Applications (2014-2016)

  • 30/08/2019
  • Articles

Officials of the European Medicines Agency (“EMA”) and the US Food and Drug Administration (“FDA”) published a study on the regulatory outcome of 107 new medicine marketing applications submitted to both agencies in the period 2014 – 2016 (the “Study”* – see attached). The Study shows that there was a high rate of convergence between the decisions on marketing approvals of both agencies.
 
The decisions upon first submission and review presented the same regulatory outcome for 91.5% of the applications (98 cases out of 107). That impressive figure rose to 98% as a result of resubmitted and reexamined applications (105 cases out of 107). Only two medicines, namely corifollitropin alfa and ataluren, were the subject of discordant marketing authorisation decisions.
 
The Study also reveals that the broad alignment between the agencies on medicine approvals coexists with some variation in type of marketing authorisation. In addition, some concordant approval decisions exhibited differences in the approved indication.
 
The divergent outcome upon first submission and review in the 9 cases referred to above were due to a difference in conclusions regarding efficacy (3 out of 9 medicines) and more disparate reasons such as dissimilarities in the submitted clinical data; and differing conclusions about the strength of evidence in support of safety or an applicant’s compliance with good manufacturing practices.
 
According to the Study, the therapeutic areas that stood out from the perspective of outcome divergence were oncology and hematology.
 
It is hoped that EMA and FDA officials will carry out similar studies in years to come as these may inform future policy decisions.   
 

 
*M. Kashoki, Z. Hanaizi, S. Yordanova, R. Vesely, C. Bouygues, J. Llinares and S. Kweder, “A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance and Why”, Clinical Pharmacology and Therapeutics, July 2019. 

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 11/09/2019
    • Articles

    Stella Kyriakides Commissioner-Designate for Health

    Stella Kyriakides, a member of the Cypriot parliament, a trained psychologist and a forceful advocate of patient rights (she is a past President of Europa Donna, the breast cancer patient group), has been entrusted with the health portfolio by Ursula von der Leyen, the President-elect of the incoming European Commission. Like the other designated Commissioners, Ms. Kyriakides’ appointment still has to be approved by the European Parliament, but with her colleagues she is expected to take up her position in November 2019.

    Read more
    • 09/09/2019
    • Articles

    Belgium - Minister of Economic Affairs Uses Price Regulation Powers against Leadiant's CDCA

    Minister of Economic Affairs Wouter Beke took action against pharmaceutical firm Leadiant and, making use of his price regulation powers, reduced the price of chenodeoxycholic acid Leadiant (“CDCA”), a medicine indicated for the treatment of patients afflicted with cerebrotendinous xanthomatosis, a rare metabolic disorder (“CTX”). CDCA was designated as an orphan medicine in December 2014, but its active substance is no longer patented and has been used for many years as an inexpensive treatment for cholesterol gallstones. In a press release (see attached, only the Dutch version is available), the Minister says that he lowered the price of what would seem to be a presentation of 100 tablets of 250mg of CDCA Leadiant to EUR 3,653.25 ex factory, while Leadiant had sought a price of EUR 14,000 ex factory. The presentation at issue covers the treatment of CTX during approximately one month. The Minister has also urged the Belgian Competition Authority (“BCA”) to review as a matter of priority the alleged abuse of a dominant position of which Leadiant might be guilty. The case before the BCA results from a complaint filed by consumer organisation Test-Aankoop/Test-Achats earlier this year (see, Van Bael & Bellis Life Sciences Newsflashes of 9 April 2019 and 11 February 2019). Additionally, the Minister called on the European Commission to review the rules governing orphan medicines. However, that call is superfluous as an assessment of these rules has already been under way for quite some time (see, Van Bael & Bellis Life Sciences Newsflash of 18 October 2018) and the outcome of this exercise is expected to be high on the agenda of the incoming European Commission.

    Read more
    • 05/09/2019
    • News

    Medicines Cooperation - Sweden to Join International Horizon Scanning Initiative

    On 4 September 2019, the Dutch Minister for Medical Care, Bruno Bruins, announced plans for Sweden to join the impending International Horizon Scanning Initiative (“IHSI”) (see, attached press release). IHSI, which is expected to start in October 2019, is a form of international cooperation that seeks to identify innovative medicines before they reach the market. It will inform decision-making on treatment and budgets in the participating countries. IHSI is just one example of a broader trend of expanding international cooperation on medicines in a range of areas and in varying geographical constellations. Last month, Minister Bruins had already announced that Canada would also become a member of IHSI (see, Van Bael & Bellis Life Sciences Newsflash of 18 July 2019). When airing the intentions of Sweden, Minister Bruins expressed the hope that IHSI would be able to begin operations with 10 member countries. Other known aspiring members include Belgium, Ireland, Luxemburg and The Netherlands.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *